Research analysts at Oppenheimer started coverage on shares of Biohaven Pharmaceutical (NYSE:BHVN) in a report issued on Monday, Marketbeat reports. The firm set a “buy” rating and a $63.00 price target on the stock. Oppenheimer’s price target indicates a potential upside of 70.73% from the stock’s current price.

A number of other equities analysts have also recently weighed in on BHVN. ValuEngine cut shares of Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Monday, August 20th. Canaccord Genuity reaffirmed a “buy” rating and set a $43.00 price target on shares of Biohaven Pharmaceutical in a research report on Friday, August 17th. Piper Jaffray Companies set a $48.00 price target on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a research report on Thursday, August 16th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $57.00 price target on shares of Biohaven Pharmaceutical in a research report on Friday, October 12th. Finally, Zacks Investment Research cut shares of Biohaven Pharmaceutical from a “hold” rating to a “strong sell” rating in a research report on Tuesday, August 14th. Two analysts have rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company’s stock. Biohaven Pharmaceutical presently has a consensus rating of “Buy” and a consensus target price of $49.56.

NYSE:BHVN opened at $36.90 on Monday. The stock has a market capitalization of $1.56 billion, a price-to-earnings ratio of -7.38 and a beta of 1.25. Biohaven Pharmaceutical has a 1-year low of $16.50 and a 1-year high of $44.28.

Biohaven Pharmaceutical (NYSE:BHVN) last posted its quarterly earnings data on Tuesday, August 14th. The company reported ($1.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.68) by $0.67. As a group, equities research analysts predict that Biohaven Pharmaceutical will post -5.41 earnings per share for the current year.

Several hedge funds have recently modified their holdings of the company. Swiss National Bank lifted its position in shares of Biohaven Pharmaceutical by 8.3% during the third quarter. Swiss National Bank now owns 33,900 shares of the company’s stock worth $1,273,000 after purchasing an additional 2,600 shares during the last quarter. United Services Automobile Association lifted its holdings in Biohaven Pharmaceutical by 20.1% in the second quarter. United Services Automobile Association now owns 16,420 shares of the company’s stock worth $649,000 after acquiring an additional 2,743 shares during the last quarter. Legal & General Group Plc lifted its holdings in Biohaven Pharmaceutical by 111.3% in the first quarter. Legal & General Group Plc now owns 5,626 shares of the company’s stock worth $145,000 after acquiring an additional 2,963 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its holdings in Biohaven Pharmaceutical by 24.7% in the second quarter. State Board of Administration of Florida Retirement System now owns 15,913 shares of the company’s stock worth $629,000 after acquiring an additional 3,150 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in Biohaven Pharmaceutical by 602.4% in the third quarter. Tower Research Capital LLC TRC now owns 5,057 shares of the company’s stock worth $190,000 after acquiring an additional 4,337 shares during the last quarter. 81.49% of the stock is currently owned by institutional investors and hedge funds.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases.

Read More: What is insider trading?

Analyst Recommendations for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.